Your browser doesn't support javascript.
loading
TUDCA: An Agonist of the Bile Acid Receptor GPBAR1/TGR5 With Anti-Inflammatory Effects in Microglial Cells.
Yanguas-Casás, Natalia; Barreda-Manso, M Asunción; Nieto-Sampedro, Manuel; Romero-Ramírez, Lorenzo.
Affiliation
  • Yanguas-Casás N; Departamento de Neurobiología Funcional y de Sistemas Instituto Cajal (CSIC), Madrid, Spain.
  • Barreda-Manso MA; Departamento de Neurobiología Funcional y de Sistemas Instituto Cajal (CSIC), Madrid, Spain.
  • Nieto-Sampedro M; Unidad de Neurología Experimental, Hospital Nacional de Parapléjicos (SESCAM), Toledo, Spain.
  • Romero-Ramírez L; Departamento de Neurobiología Funcional y de Sistemas Instituto Cajal (CSIC), Madrid, Spain.
J Cell Physiol ; 232(8): 2231-2245, 2017 Aug.
Article in En | MEDLINE | ID: mdl-27987324
Bile acids are steroid acids found in the bile of mammals. The bile acid conjugate tauroursodeoxycholic acid (TUDCA) is neuroprotective in different animal models of stroke and neurological diseases. We have previously shown that TUDCA has anti-inflammatory effects on glial cell cultures and in a mouse model of acute neuroinflammation. We show now that microglial cells (central nervous system resident macrophages) express the G protein-coupled bile acid receptor 1/Takeda G protein-coupled receptor 5 (GPBAR1/TGR5) in vivo and in vitro. TUDCA binding to GPBAR1/TGR5 caused an increase in intracellular cAMP levels in microglia that induced anti-inflammatory markers, while reducing pro-inflammatory ones. This anti-inflammatory effect of TUDCA was inhibited by small interference RNA for GPBAR1/TGR5 receptor, as well as by treatment with a protein kinase A (PKA) inhibitor. In the mouse model of acute neuroinflammation, treating the animals with TUDCA was clearly anti-inflammatory. TUDCA biased the microglial phenotype in vivo and in vitro toward the anti-inflammatory. The bile acid receptor GPBAR1/TGR5 could be a new therapeutic target for pathologies coursing with neuroinflammation and microglia activation, such as traumatic brain injuries, stroke, or neurodegenerative diseases. TUDCA and other GPBAR1/TGR5 agonists need to be further investigated, to determine their potential in attenuating the neuropathologies associated with microglia activation. J. Cell. Physiol. 232: 2231-2245, 2017. © 2016 Wiley Periodicals, Inc.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Taurochenodeoxycholic Acid / Prosencephalon / Microglia / Neuroprotective Agents / Receptors, G-Protein-Coupled / Encephalitis / Hippocampus / Anti-Inflammatory Agents Type of study: Prognostic_studies Limits: Animals Language: En Journal: J Cell Physiol Year: 2017 Document type: Article Affiliation country: Spain Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Taurochenodeoxycholic Acid / Prosencephalon / Microglia / Neuroprotective Agents / Receptors, G-Protein-Coupled / Encephalitis / Hippocampus / Anti-Inflammatory Agents Type of study: Prognostic_studies Limits: Animals Language: En Journal: J Cell Physiol Year: 2017 Document type: Article Affiliation country: Spain Country of publication: United States